CCN2 and rhabdomyosarcoma: For example, in human rhabdomyosarcoma, CCN2 has been demonstrated to be a useful therapeutic agent and disrupting CCN2 expression using CCN2-neutralizing antibodies can enhance apoptosis and inhibit angiogenesis [33].